

## PRICE SENSITIVE INFORMATION

This is for information of all concerned that the Board of Directors of Indo-Bangla Pharmaceuticals Ltd. in its Board Meeting held on 10<sup>th</sup> June 2020 at 4:00 p.m. at its Corporate Office, Plot # 183 (7<sup>th</sup> Floor), Block # B, Ahmed Akbar Sobhan Road, Bashundhara R/A, Dhaka-1229 approved the Third Quarter (Q 3) Un-Audited Financial Statements for the period ended 31<sup>st</sup> March, 2020.

The key financial highlights for the Third Quarter period ended 31<sup>th</sup> March 2020 are appended below:

		9 months		3 months	
CI	Particulars	July to March		January to March	
SL No.		2019-2020	2018-2019	2019-2020	2018-2019
	Earnings Per Share (EPS)	1.26	1.03	0.42	0.39
	Net Operating Cash Flows Per Share (NOCFPS)	1.31	0.89	-	-
		As at 31 <sup>st</sup> March, 2020		As at 30 <sup>th</sup> June, 2019	
	Net Asset Value (NAV) per share	13.47		13.44	
		By order of the Board of Directors			
	Date: 10 <sup>th</sup> June, 2020 Dhaka.	(Mohi Uddin, QCS)			
		Company secretary			

This Price Sensitive Information is also available in our website: www.indo-bangla-banglapharma.com.

Indo-Bangla Pharmaceuticals Ltd. Plot- 183 (7<sup>th</sup> Floor), Block-B, Main Road, Bashundhara R/A Dhaka-1229.

Tel-09678777995 <u>E-mail-info@indo-banglapharma.com</u> Web- www.indo-banglapharma.com.